Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Diagnostic Device Identifies COVID-19 Patients at Risk of Potentially Lethal Cytokine Storm

By LabMedica International staff writers
Posted on 19 Feb 2021
Researchers have developed a diagnostic device, called an Immuno-storm chip, that could identify which cancer and COVID-19 patients are at risk of a potentially lethal ‘cytokine storm’.

The device was invented by scientists from the Australian Institute for Bioengineering and Nanotechnology (AIBN) at The University of Queensland (Queensland, Australia) and could help healthcare workers triage and closely monitor high risk patients and to begin treatment much earlier.

Cytokines are small proteins that act as messengers between cells in the immune system. More...
They play a critical role in triggering inflammation by stimulating the movement of immune cells toward sites of injury or infection. However, if the release of cytokines becomes uncontrolled, this causes hyperinflammation which damages tissue. This, in turn, causes more cytokines to be released in a vicious, potentially lethal cycle called a ‘cytokine storm’. Cytokine storms can arise during a variety of diseases, as well as in response to immune-therapies. Unfortunately, it’s very difficult to predict who will develop a cytokine storm. Until recently, they were thought to arise very suddenly, but there is now evidence that a very faint but distinctive pattern of cytokines begins to emerge several days before the full-blown storm.

Scientists at the AIBN have developed a nanotechnology device, called an Immuno-storm chip, that can detect this early warning signal on a miniaturized platform with minimal sample. They designed a nanoscale array of gold pillars to which they attached antibodies that stick to specific cytokines in blood. If these cytokines are present in a blood sample as small as a single drop, they will bind to the gold ‘nanopillars’. These captured cytokines are then detected by gold-silver ‘nanotag’ particles. The team designed these nanotags to emit light whenever they encounter a cytokine. The chip’s small size - about the size of a SIM card - meant the diagnostic technology could eventually be made relatively portable.

“Whether in a cancer treatment setting or when monitoring infectious diseases such as acute COVID-19, long-haul COVID-19 and sepsis, the Immuno-storm chip could provide critical medical information that guides important clinical decisions. Critically, it could inform doctors to begin, or to ease off treatments, by accurately monitoring the patient’s immune response before it goes crazy,” said Professor Matt Trau, a researcher AIBN. “Detection of the detailed cytokine signature for vulnerable COVID-19 patients with the Immuno-storm chip could also be used to personalize the therapy of these patients, tuned in to alleviate their specific excessive immune system response.”

Related Links:
The University of Queensland


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Neutralization Antibody Test
UNICELL-2019-nCoV Neutralization Antibody Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.